October 15, 2026 · Phase 2 readout
KZIA Phase 2 readout: a positive outcome, +9.0%
On October 15, 2026, Abemaciclib — KAZIA THERAPEUTICS LTD (CDK Gene Mutation) reached its Phase 2 readout. The result was a positive outcome, and the stock moved +9.0% in the window around the event. It had already run -15.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$6.79
1d before
$7.40
Event day
$7.40
1d after
$7.40
5d after
Pre-catalyst setup
-15.0%
30-day run-up
7879%
30-day volatility
2.9×
volume spike